Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agrippal S1
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Agrippal S1 is a trivalent inactivated influenza vaccine designed for the prophylaxis of influenza, especially in individuals at increased risk of influenza-associated complications. It contains purified surface antigens (haemagglutinin and neuraminidase) from three influenza virus strains propagated in fertilized hen’s eggs and inactivated with formaldehyde. The vaccine complies with WHO recommendations for seasonal influenza vaccination. It is administered as a 0.5 ml suspension via intramuscular or deep subcutaneous injection, typically provided in pre-filled syringes. The vaccine may contain trace residues of egg proteins, kanamycin sulfate, neomycin sulfate, formaldehyde, cetyltrimethylammonium bromide (CTAB), polysorbate 80, and other excipients used during manufacturing.
- Brand names
- Agrippal S1
- Other names
- Influenza-virus-vaccine-Begrivac-CSLBegrivac vaccine suspension for injection 0.5ml pre-filled syringes
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Influenza virus haemagglutinin and neuraminidaseγδ TCR (T-cell receptor)HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Agrippal S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agrippal S1.